## **WEST Search History**

DATE: Tuesday, November 25, 2003

Set Name side by side	Hit Count Set Name result set		
DB = U			
L6	L2 and (valeramide or valerate or valeric)	7	L6
L5	L2 and (isovaleramide or isovalerate or isovaleric)	0	L5
L4	L2 and (isovelaramide or isovalerate or isovaleric)	0	L4
L3	L2 and (film or cellulose) adj3 coat\$5	19	L3
L2	L1 and (matrix or core) same (hydrogel or xanthan or gum or swelling or swellable or gel or gelling or gellant)	59	L2
L1	(anxiolytic or anxiolysis or sedative or hypnotic or tranquilizer or sedation) same (sustained or prolonged or controlled) adj3 release	288	L1

END OF SEARCH HISTORY

## Help Logout Interrupt Mein Menu Search Form Posting Counts Show & Numbers Edit & Numbers Freferences Cases

## Search Results -

Term	Documents
RELEASE	886574
RELEASES	177875
SUSTAINED	96570
SUSTAINEDS	0
PROLONGED	169964
PROLONGEDS	0
CONTINUOUS	1327338
CONTINUOU	54
(9 SAME (RELEASE ADJ3 (SUSTAINED OR PROLONGED OR CONTINUOUS))).USPT,PGPB,JPAB,EPAB,DWPI.	0
(L9 SAME RELEASE ADJ3 (SUSTAINED OR PROLONGED OR CONTINUOUS)).USPT,PGPB,JPAB,EPAB,DWPI.	0

Database:	BM Technical Disclosure Bulletins    ▲	
Search:	L13	Refine Search
	Recall Text Clear	K:
	Search History	

DATE: Tuesday, November 25, 2003 Printable Copy Create Case

Set Name side by side	Hit Count	Set Name result set	
DB = U	SPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR		
<u>L13</u>	L9 same release adj3 (sustained or prolonged or continuous)	0	<u>L13</u>
<u>L12</u>	L9 and release adj3 (sustained or prolonged or continuous) and (hydrogel or gelling or gum or polysaccharide or cellulose)	10	<u>L12</u>
<u>L11</u>	L9 and release adj3 (sustained or prolonged or continuous) and (core or matrix) same (hydrogel or gelling or gum or polysaccharide or cellulose)	1	<u>L11</u>
<u>L10</u>	L9 and l1	2	<u>L10</u>
<u>L9</u>	isovaleramide or isovaleric	2990	<u>L9</u>
<u>L8</u>	L7 and (anxiolytic or anxiety or hypnotic or sedative)	1	<u>L8</u>
<u>L7</u>	L1 and matrix same (hydrogel or gelling or gum or polysaccharide or cellulose)	10	<u>L7</u>
<u>L6</u>	L2 and (anxiolytic or anxiety or hypnotic or sedative)	0	<u>L6</u>
<u>L5</u>	L4 and (anxiolytic or anxiety or hypnotic or sedative)	0	<u>L5</u>
<u>L4</u>	L1 and core same (hydrogel or gelling or gum or polysaccharide or cellulose)	9	<u>L4</u>
<u>L3</u>	L1 and matrix same core same (hydrogel or gelling or gum or polysaccharide or cellulose)	0	<u>L3</u>
<u>L2</u>	L1 and matrix same core	19	<u>L2</u>
<u>L1</u>	release adj3 (sustained or prolonged or continuous) same (hydrophilic or water adj soluble ) adj5 (compound or active or drug or therapeutic or pharmaceutical)	106	<u>L1</u>

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 10:53:37 ON 25 NOV 2003)

	(FIDE HOME ENTE	KED AT 10:53:	37 ON 25 NOV 2003)
	• • • • • • • • • • • • • • • • • • • •	NTERED AT 10:	53:49 ON 25 NOV 2003
L1	. 1 SEA ABI D L1	B=ON PLU=ON	ISOVALERAMIDE/CN
L2		B=ON PLU=ON	ISOVALERATE/CN
L3		B=ON PLU=ON	"ISOVALERIC ACID"/CN
	FILE 'CAPLUS' ENT	ERED AT 10:55	:44 ON 25 NOV 2003
L4	PROLON		(L1 OR L2 OR L3) AND (SUSTAINED OR LLED) (2A) RELEASE
L5		B=ON PLU=ON	(L1 OR L2 OR L3) AND (TABLET OR CAPSULE OR
L6	0 SEA AB	B=ON PLU=ON	L5 AND (MATRIX OR CORE) (P) (GELLING OR OLYSACCHARIDE OR HYDROGEL)
L7	2 SEA AB OR GEL D L7 I	B=ON PLU=ON	L5 AND (SWELLING OR SWELLABLE OR GELLING R POLYSACCHARIDE OR HYDROGEL)
L8	(SUSTA	INED OR PROLO BLE OR GELLIN	(TABLET OR CAPSULE OR DOSAGE FORM) (P) NGED) (3A) RELEASE AND (SWELLING OR G OR GELLANT OR GUM OR POLYSACCHARIDE OR
L9	(SUSTA (SWEL)	INED OR PROLO	(TABLET OR CAPSULE OR DOSAGE FORM) (P) NGED) (3A) RELEASE AND (CORE OR MATRIX) (P) LABLE OR GELLING OR GELLANT OR GUM OR YDROGEL)
L10			L9 AND (FILM OR RETARDANT) (3A) COAT?
L11	OR HYP	B=ON PLU=ON NOTIC OR CNS IBIB KWIC	L10 AND (ANXIETY OR ANXIOLYTIC OE SEDATIVE DISORDER)
L12	1 SEA AB OR HYP		L10 AND (ANXIETY OR ANXIOLYTIC OR SEDATIVE DISORDER)

L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1993:132151 CAPLUS

DOCUMENT NUMBER: 118:132151

TITLE: Therapeutic nutrients containing glycerides of

branched chain fatty acids

INVENTOR(S): Sommermeyer, Klaus

PATENT ASSIGNEE(S): Fresenius A.-G., Germany

SOURCE: Ger. Offen., 6 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.		KIND	DATE		APPLICATION NO.	DATE
DE 4116004		A1	19921119		DE 1991-4116004	19910516
DE 4116004		C2	19930930			
WO 9220241		A1	19921126		WO 1992-EP1049	19920513
W: JP	, US					
RW: AT	, BE,	CH, DE	, DK, ES,	FR,	GB, GR, IT, LU, MC,	NL, SE
EP 584159		A1	19940302		EP 1992-910171	19920513
EP 584159		B1	19951227			
R: AT	, BE,	CH, DE	, DK, ES,	FR,	GB, GR, IT, LI, LU,	NL, SE
JP 0651138	4	T2	19941222		JP 1992-509184	19920513
AT 132012		E	19960115		AT 1992-910171	19920513
ES 2081108		Т3	19960216		ES 1992-910171	19920513
US 5492713		A	19960220		US 1994-150039	19940805
PRIORITY APPLN.	INFO	. :		D.	E 1991-4116004	19910516
				W	O 1992-EP1049	19920513

OTHER SOURCE(S): MARPAT 118:132151

AB Glycerides contg. branched fatty acids, MeRCH(CH2)m(CH2)nCO2H (R = Me, Et; n = 0 or even no. from 2-18; m = 0,1) are used in therapeutic diets for treatment of trauma and sepsis, esp. uremia. These may be used in oral or parenteral formulations. These fatty acids act as a source of branched-chain keto-acids for use in branched chain amino acid biosynthesis to maintain protein synthesis in the liver. The prepn. of glyceryl triisovalerinate, glyceryl tri-(3-methylvalerinate), and glyceryl tri-(4-methylvalerinate) by acid-catalyzed esterification is demonstrated. Formulations and dosage forms (capsules) using these glycerides are described.

IT Pharmaceutical dosage forms

(capsules, contg. glycerides of branched-chain fatty acids, for treatment of uremia)

IT Pharmaceutical dosage forms

(emulsions, contg. glycerides of branched-chain fatty acids, for treatment of uremia)

IT 105-43-1, 3-Methylvaleric acid 503-74-2, Isovaleric acid

646-07-1, 4-Methylvaleric acid

RL: RCT (Reactant); RACT (Reactant or reagent)

L5 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1991:506014 CAPLUS

DOCUMENT NUMBER: 115:106014

TITLE: Short-chain fatty acids for treating inflammatory

bowel disorders

INVENTOR(S): Breuer, Richard I.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE: Eng: FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	PATENT NO.			KIND DATE				APPLICATION NO					. DATE		
WO	9107: W:		FI,			1991	0530		W	0 19	90-U	 S669	7	1990111	5
			•	•		, DK,	ES,	FR,	GB,	GR,	IT,	LU,	NL,	, SE	
US	5039													1989111	6
CA	20712								C	A 19	90-2	0712	15	1990111	5
CA	20712	215		С		1997	0204						`		
EP	50292	25		A	1	1992	0916		Ε	P 19	91-9	0010	2	1990111	5
EP	50292	25		В	1	1996	0925								
	R:	AT,	BE,	CH,	DE,	, DK,	ES,	FR,	GB,	GR,	ΙT,	LI,	LU,	, NL, SE	
AT	1432	51		Ε		1996	1015		A	T 19	91-9	0010	2	1990111	5
ES	2093			_	-	1997	0101		E	S 19	91-9	0010	2	1990111	5
ΙL	9636	5		A	1	1995	0629		I	L 19	90-9	6365		1990111	6
AU	90668	317		Α	1	1991	0523		A	U 19	990-6	6817		1990112	1
AU	9350	516		A	1	1994	0113		Α	U 19	93-5	0516		1993110	8
AU	6644	92		B	2	1995	1116								
PRIORIT	Y APP	LN.	INFO	. :				1	US 1	989-	4382	97		1989111	6
								1	WO 1	990-	-US66	97		1990111	5

## IT Pharmaceutical dosage forms

(enemas, short-chain fatty acids in, for colon inflammation treatment)
IT 64-19-7, Acetic acid, biological studies 79-09-4, Propanoic acid,
biological studies 79-31-2, Isobutyric acid 107-92-6, Butyric acid,
biological studies 109-52-4, Valeric acid, biological studies
503-74-2, Isovaleric acid 135852-25-4

RL: BIOL (Biological study)

(colon inflammation treatment with)